

Express Mail No. EV335855683US

ATTY. DOCKET NO.	APPLICATION NO.
9516-0048-999	10/032,286
APPLICANT	
Robarge et al.	
FILING DATE	GROUP
December 21, 2001	1625

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
cc	AA	3,992,189	11/16/76	Goddard			
	AB	5,045,108	9/3/91	Elbe et al.			
	AC	5,198,402	3/30/93	Kaji et al.			
	AD	5,326,800	7/5/94	Horn et al.			
	AE	5,385,901	1/31/95	Kaplan et al.			
	AF	5,605,914	2/25/97	Muller			
	AG	5,635,517	6/3/97	Muller et al.			
	AH	5,658,940	8/19/97	Muller et al.			
	AI	5,698,579	12/16/97	Muller			
	AJ	5,703,098	12/30/97	Muller et al.			
	AK	5,728,845	3/17/98	Muller et al.			
	AL	5,736,570	4/7/98	Muller et al.			
	AM	5,798,368	8/25/98	Muller et al.			
	AN	5,801,195	9/1/98	Muller et al.			
	AO	5,874,448	2/23/99	Muller et al.			
	AP	5,877,200	3/2/99	Muller			
	AQ	5,929,117	7/27/99	Muller et al.			
	AR	5,955,476	9/21/99	Muller et al.			
	AS	5,968,945	10/19/99	Muller et al.			
	AT	6,011,050	1/4/00	Muller et al.			
	AU	6,020,358	2/1/00	Muller et al.			
	AV	6,046,221	4/4/00	Muller et al.			
	AW	6,075,041	6/13/00	Muller			
	AX	6,130,226	10/10/00	Muller et al.			
	AY	6,180,644	1/30/01	Muller et al.			
	AZ	6,200,987	3/13/01	Muller			
cc	BA	6,214,857	4/10/01	Muller et al.			


TECH CENTER 1600/2400

JUN 25 2003

RECEIVED

Elong

4/15/04



# FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BE	EP 0 797 437	10/1/97	Europe				
	BC	EP 1 004 572	5/31/00	Europe				
	BD	EP 1 004 580	5/31/00	Europe				
	BE	EP 1 004 581	5/31/00	Europe				
	BF	WO 00/25777	5/11/00	PCT				
	BG	WO 00/38521	7/6/00	PCT				
	BH	WO 00/55134	9/21/00	PCT				
	BI	WO 92/18496	10/29/92	PCT				
	BJ	WO 95/01348	1/12/95	PCT				
	BK	WO 96/20705	7/11/96	PCT				
	BL	WO 96/20926	7/11/96	PCT				
	BM	WO 97/08143	3/6/97	PCT				
	BN	WO 97/12859	4/10/97	PCT				
	BO	WO 97/23457	7/3/97	PCT				
	BP	WO 97/37988	10/16/97	PCT				
	BQ	WO 98/03502	1/29/98	PCT				
	BR	WO 98/06692	2/19/98	PCT				
	BS	WO 98/24763	6/11/98	PCT				
	BT	WO 98/41525	9/24/98	PCT				
	BU	WO 98/54170	12/3/98	PCT				
	BV	WO 99/06041	2/11/99	PCT				
	BW	WO 99/46258	9/16/99	PCT				
	BX	WO 99/47512	9/23/99	PCT				

TECH CENTER 1600/2900

JUN 26 2003

RECEIVED

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

a	BY	Corral et al., 1999, "Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF- $\alpha$ ", J Immunol.163:380-386
	BZ	He et al., 1993, "Synthesis of thalidomide analogs and their biological potential for treatment of graft versus host disease", Abstracts of Papers, 206 <sup>th</sup> ACS National Meeting, Abstract No. 216
	CA	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity", J. Med. Chem. 39:3238-3240
	CB	Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition" Bioorg. Med. Chem. Lett. 8:2669-2674
a	CC	Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF- $\alpha$ production", Bioorg. Med. Chem. Lett. 9:1625-1630


EXAMINER

*Ch*

DATE CONSIDERED

4/15/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
JUN 26 2003  
TECH CENTER 1600/2003

LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)

ATTY DOCKET NO.  
9516-0048-999

APPLICATION NO  
10/032,286

APPLICANT  
Robarge *et al.*

FILING DATE  
December 21, 2001

GROUP  
1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
u	CD	3,992,189	11/16/76	Goddard			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
u	CE	WO 97/45117	12/4/97	PCT			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

u	CF	Bundgaard, "Design of prodrugs" Elsevier, Amsterdam - New York - Oxford, p.27-43 (1986).
	CG	Corral et al., 1996, "Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity" Mol. Med. Jul;2(4):506-15
	CH	Database CAPLUS on STN (Columbus, OH, USA), No. 118:131893, 'The hydrolysis of azidoprofen esters: a model for a soft anti-inflammatory drug for topical application' Int. J. Phar. Vol. 89, p. 65-74 (1993), abstract.
	CI	Database CAPLUS on STN (Columbus, OH, USA), No. 128:140615, 'Substituted 2-(2,6-dioxo-3-piperidinyl)phthalimides and 1-oxoisindolines and method of reducing TNF-alpha levels' WO98/03502, abstract and registry no. 191732-76-0, 202271-87-2, 202271-88-3, 202271-89-4, 202271-90-7.
	CJ	Database CAPLUS on STN (Columbus, OH, USA), No. 130:38290, 'Substituted 2-(2,6-dioxo-3-piperidinyl)phthalimides and 1-oxoisindolines and method of reducing TNF-alpha levels' WO98/54170, abstract and registry no. 202271-88-3, 216669-27-1; 191732-72-6.
	CK	Database CAPLUS on STN (Columbus, OH, USA), No. 131:214197, 'Preparation of 2-(2,6-dioxo-3-fluoropiperidin-3-yl) isoindolines for reducing inflammatory cytokine levels' US 5,955,476, abstract and registry no. 220460-56-0, 220460-57-1, 220460-62-8, 220460-64-0.
	CL	Marriott et al., 2001, "Immunotherapeutic and antitumor potential of thalidomide analogue" Expert Opin. Biol. Ther. Jul;1(4):675-82. Review
	CM	Miyachi et al. 1998, "Tumor necrosis factor-alpha production enhancing activity of substituted 3'-methylthalidomide: influence of substituents at the phthaloyl moiety on the activity and stereoselectivity" Chem. Pharm. Bull. (Tokyo). Jul;46(7):1165-8.
u	CN	Price et al., 2002, "5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis" Ther. Drug monit. Feb;24(1):104-10.

EXAMINER

eb

DATE CONSIDERED

1/15/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.